

SURVEILLANCE REPORT

Adverse Events Following Immunization (AEFIs) for COVID-19 in Ontario: December 13, 2020 to December 3, 2023

This report provides a summary of adverse events following immunization (AEFIs) that are temporally associated (i.e., occur after receiving the vaccine) with receipt of COVID-19 vaccine and meet the [provincial surveillance definitions](#) (i.e., confirmed).¹ It is important to note that AEFIs described in this report are defined as any untoward medical occurrences that followed immunization and do not necessarily have a causal relationship with the vaccine.

This summary includes AEFIs reported in the Public Health Case and Contact Management Solution (CCM) as of **December 3, 2023** and doses administered up to and including **December 3, 2023** in the Ontario Ministry of Health's COVaxON application (see [technical notes](#) for details on data sources). Data were extracted on December 4, 2023. This report is updated every 4 weeks.

Background

In Ontario, AEFIs are reported to local public health units (PHUs) by health care providers and vaccine recipients.² PHUs investigate and assess all AEFI reports, which are then entered into the provincial electronic reporting system according to [provincial surveillance guidelines](#).¹ Please see the following resources for more information:

- Public Health Ontario's (PHO) [overview of vaccine safety surveillance](#) for more information on vaccine safety surveillance in Ontario³
- The [technical annex](#) of PHO's annual vaccine safety report for technical details on vaccine safety surveillance data analysis in Ontario⁴
- The government of Canada's COVID-19 vaccine safety [webpage](#) for national data on COVID-19 vaccine safety⁵
- PHO's [COVID-19 vaccine webpage](#) for resources and data on Ontario's COVID-19 vaccine program

Highlights

There are a total of 23,127 AEFI reports received following 39,806,128 doses of COVID-19 vaccines administered in Ontario to date with a reporting rate of 58.1 per 100,000 doses administered (0.06 % of all doses administered). This represents an increase of 83 new AEFI reports compared to the previous report.

Of the total 23,127 AEFI reports received to date:

- 21,863 AEFI reports are non-serious (94.5% of total AEFI reports)
- 1,264 AEFI reports meet the [serious definition](#) (5.5% of total AEFI reports)
- The most commonly reported adverse events are ‘other severe or unusual events’ and ‘allergic skin reactions’, reported in 28.3% and 22.5% of the total AEFI reports, respectively
- 1,753 reports include a COVID-19 vaccine-specific adverse event of special interest, in which 763 reports also meet the serious definition (see [Adverse events of special interest](#) section for more information)

To date, two safety signals have been confirmed for COVID-19 vaccines based on AEFIs reported in Canada during the COVID-19 vaccination program roll-out: Thrombosis with thrombocytopenia syndrome (TTS) and myocarditis/pericarditis. These two signals were also detected internationally. Refer to the [Adverse Event section](#) of this report for more information. Ontario is continuing to monitor all AEFIs reported following receipt of COVID-19 immunization in collaboration with its partners.

In Ontario, AEFIs that meet the serious definition are events that required hospital admission and reports of death. Please see the [technical notes](#) for a full definition of serious AEFIs.

Several adverse events have been identified as COVID-19 vaccine-specific adverse events of special interest (AESIs). The list of COVID-19 specific AESIs are listed in the [technical notes](#).

Summary of AEFI reports in Ontario

An AEFI report refers to a report received by the PHU, which pertains to one individual vaccine recipient who reported at least one adverse event after receiving the COVID-19 vaccine (i.e., temporally associated with the vaccine). COVID-19 vaccines may be administered concomitantly with, or at any time before or after non-COVID-19 vaccines including live, non live, adjuvanted, or unadjuvanted vaccines for people 6 months of age or older.⁶ See [Table 1](#) for a summary of all AEFI reports received to date in Ontario.

Table 1. Summary of AEFI reports by COVID-19 vaccine product: Ontario, December 13, 2020 to December 3, 2023

	Pfizer-BioNTech Comirnaty	Pfizer-BioNTech Comirnaty Bivalent BA.4/5	Pfizer-BioNTech Comirnaty XBB.1.5	Moderna Spikevax	Moderna Spikevax Bivalent BA.1	Moderna Spikevax Bivalent BA.4/5	Moderna Spikevax XBB.1.5	AstraZeneca Vaxzevria/COVISHIELD	Janssen Jcovden (Johnson & Johnson)	Novavax Nuvaxovoid	All vaccine products combined
Total number of AEFI reports	13,660	190	26	7,309	120	41	30	1,696	20	33	23,127
Number of non-serious reports	12,959	173	25	6,911	112	39	25	1,564	20	33	21,863
Number of serious reports	701	17	1	398	8	2	5	132	0	0	1,264
Proportion of total AEFI reports that are serious (%)	5.1	8.9	3.8	5.4	6.7	4.9	16.7	7.8	0.0	0.0	5.5
Doses administered	3,617,169	2,315,865	1,186,048	9,633,286	1,255,694	140,718	547,855	1,087,696	3,998	16,512	39,806,128
Total reporting rate per 100,000 doses administered	57.8	8.2	2.2	75.9	9.6	29.1	5.5	155.9	500.3	199.9	58.1
Serious reporting rate per 100,000 doses administered	3.0	0.7	0.1	4.1	0.6	1.4	0.9	12.1	0.0	0.0	3.2

Notes:

- The columns above for Pfizer-BioNTech Comirnaty and Moderna Spikevax COVID-19 vaccines include AEFIs associated with all indicated dosages: 3 mcg, 10 mcg and 30 mcg for Pfizer-BioNTech Comirnaty and 25 mcg, 50 mcg and 100 mcg for Moderna Spikevax. Moderna Spikevax Bivalent BA.1 (50 mcg), Moderna Spikevax Bivalent BA.4/5 (50 mcg) and Pfizer-BioNTech Comirnaty Bivalent BA.4/5 (10 mcg and 30 mcg) COVID-19 vaccines are presented separately and were previously recommended vaccine products before the approval of the XBB.1.5-containing COVID-19 mRNA vaccines. Currently, Pfizer-BioNTech Comirnaty XBB.1.5 and Moderna Spikevax XBB.1.5 COVID-19 vaccines are approved and recommended for vaccinating individuals who were not previously vaccinated and as additional doses for those previously vaccinated in approved age groups.
- Two AEFI reports did not specify a vaccine product received.
- Reporting rate for the Janssen Jcovden (Johnson & Johnson), Novavax Nuvaxovid, and Moderna Spikevax Bivalent BA.4/5 COVID-19 vaccines should be interpreted with caution due to unstable reporting rate arising from the relatively small number of doses administered.

Data Source: CCM, COVaxON (see [technical notes](#) for details on data sources)

Table 2. Number of AEFI reports and reporting rates by age group and sex: Ontario, December 13, 2020 to December 3, 2023


	Number of AEFI reports received to date	Reporting rate per 100,000 doses administered
Sex: Female	16,934	81.4
Sex: Male	5,949	31.4
Ages: 0-4 years	60	44.0
Ages: 5-11 years	329	25.4
Ages: 12-17 years	818	39.1
Ages: 18-24 years	1,448	46.8
Ages: 25-29 years	1,429	57.0
Ages: 30-39 years	3,725	73.7
Ages: 40-49 years	4,512	92.4
Ages: 50-59 years	4,409	74.6
Ages: 60-69 years	3,484	52.4
Ages: 70-79 years	1,935	37.8
Ages: 80 years and over	973	32.4

Note:

- Age represents age at time of immunization. Gender is used when sex is missing. Some AEFI reports and doses administered records have unknown sex, gender or age; these reports are excluded from sex and age-specific counts and reporting rates.

Data Source: CCM, COVaxON (see [technical notes](#) for details on data sources)

Figure 1. Number of AEFI reports and doses administered by week of vaccine administration: Ontario, December 13, 2020 to December 3, 2023



Note:

- AEFI reports are assessed based on date of vaccine administration. The administration week ranges from week 51 (Dec 13 – 19, 2020) to week 48 (November 26 – December 2, 2023). December 3, 2023 is not included in the figure as it is not yet a full week.
- The number of AEFI reports for the recent reporting weeks are subject to reporting delays and/or delayed data entry (i.e., reports are likely to still be under investigation and yet to be reported as a confirmed AEFI report).

Data Source: CCM, COVaxON (see [technical notes](#) for details on data sources)

Table 3. Number of AEFI reports and reporting rates by COVID-19 vaccine product and dose number: Ontario, December 13, 2020 to December 3, 2023

	Pfizer-BioNTech Comirnaty	Pfizer-BioNTech Comirnaty Bivalent BA.4/5	Pfizer-BioNTech Comirnaty XBB.1.5	Moderna Spikevax	Moderna Spikevax Bivalent BA.1	Moderna Spikevax Bivalent BA.4/5	Moderna Spikevax XBB.1.5	AstraZeneca Vaxzevria/COVISHIELD	Janssen Jcovden (Johnson & Johnson)	Novavax Nuvaxovoid	All vaccine products combined
Total number of AEFI reports	13,660	190	26	7,309	120	41	30	1,696	20	33	23,127
Dose 1	8,549	0	0	3,678	0	2	0	1,615	19	18	13,882
Dose 2	4,046	0	0	2,510	0	2	0	78	1	12	6,650
Dose 3	893	10	0	894	4	2	0	0	0	1	1,804
Dose 4+	154	176	4	211	114	32	6	0	0	2	699
Number of serious reports	701	17	1	398	8	2	5	132	0	0	1,264
Dose 1	329	0	0	112	0	0	0	122	0	0	563
Dose 2	299	0	0	218	0	0	0	9	0	0	526
Dose 3	65	0	0	50	1	0	0	0	0	0	117
Dose 4+	7	17	1	18	7	1	0	0	0	0	51
Total reporting rate per 100,000 doses administered	57.8	8.2	2.2	75.9	9.6	29.1	5.5	155.9	500.3	199.9	58.1
Dose 1	90.8	0.0	0.0	167.7	0.0	96.3	0.0	187.0	498.4	337.2	110.7
Dose 2	49.8	0.0	0.0	68.0	0.0	140.5	0.0	34.9	952.4	237.9	55.1
Dose 3	19.5	7.8	0.0	29.7	10.6	80.9	0.0	0.0	0.0	95.1	23.1
Dose 4+	10.3	8.2	0.3	28.7	9.4	23.7	1.2	0.0	0.0	39.4	9.4

	Pfizer-BioNTech Comirnaty	Pfizer-BioNTech Comirnaty Bivalent BA.4/5	Pfizer-BioNTech Comirnaty XBB.1.5	Moderna Spikevax	Moderna Spikevax Bivalent BA.1	Moderna Spikevax Bivalent BA.4/5	Moderna Spikevax XBB.1.5	AstraZeneca Vaxzevria/ COVISHIELD	Janssen Jcovden (Johnson & Johnson)	Novavax Nuvaxovoid	All vaccine products combined
Serious reporting rate per 100,000 doses administered	3.0	0.7	0.1	4.1	0.6	1.4	0.9	12.1	0.0	0.0	3.2
Dose 1	3.5	0.0	0.0	5.1	0.0	0.0	0.0	14.1	0.0	0.0	4.5
Dose 2	3.7	0.0	0.0	5.9	0.0	0.0	0.0	4.0	0.0	0.0	4.4
Dose 3	1.4	0.0	0.0	1.7	2.7	0.0	0.0	0.0	0.0	0.0	1.5
Dose 4+	0.5	0.8	0.1	2.4	0.6	0.7	0.0	0.0	0.0	0.0	0.7

Notes:

- Dose 4+ includes the 4th dose and all subsequent doses an individual has received. Some AEFIs have missing or unknown dose number. These reports are excluded from dose number-specific counts and reporting rates. Therefore, the sum of dose number-specific counts will not equal to the total..
- The columns above for Pfizer-BioNTech Comirnaty and Moderna Spikevax COVID-19 vaccines include AEFIs associated with all indicated dosages: 3 mcg, 10 mcg and 30 mcg for Pfizer-BioNTech Comirnaty and 25 mcg, 50 mcg and 100 mcg for Moderna Spikevax. Moderna Spikevax Bivalent BA.1 (50 mcg), Moderna Spikevax Bivalent BA.4/5 (50 mcg) and Pfizer-BioNTech Comirnaty Bivalent BA.4/5 (10 mcg and 30 mcg) COVID-19 vaccines are presented separately and were previously recommended vaccine products before the approval of the XBB1.5-containing COVID-19 mRNA vaccines. Currently, Pfizer-BioNTech Comirnaty XBB.1.5 and Moderna Spikevax XBB.1.5 COVID-19 vaccines are approved and recommended for vaccinating individuals who are not previously vaccinated and as additional doses for those previously vaccinated in approved age groups.
 - Reporting rate for the Janssen Jcovden (Johnson & Johnson), Novavax Nuvaxovoid, and Moderna Spikevax Bivalent BA.4/5 COVID-19 vaccines should be interpreted with caution due to unstable reporting rate arising from a relatively small number of doses administered.


Data Source: CCM, COVaxON (see [technical notes](#) for details on data sources)

Adverse Event Descriptions

For all COVID-19 vaccine products combined, the most commonly reported adverse events are ‘other severe or unusual events’ and ‘allergic skin reactions’, reported in 28.3% and 22.5% of the total AEFI reports, respectively. [Figure 2](#) shows the ten most frequently reported adverse events for all COVID-19 vaccines combined.

To date, two safety signals have been confirmed for COVID-19 vaccines based on AEFIs reported in Canada during the COVID-19 vaccination program roll-out: Thrombosis with thrombocytopenia syndrome (TTS) and myocarditis/pericarditis. These two signals were also detected internationally. Ontario is continuing to monitor all AEFIs reported following receipt of COVID-19 immunization in collaboration with its partners.

Figure 2. Ten most frequently reported adverse events for all COVID-19 vaccines: Ontario, December 13, 2020 to December 3, 2023



Note: An AEFI report may contain multiple adverse events. Thus the sum of all adverse event-specific counts will not equal to the total number of AEFI reports.

Data Source: CCM

The ‘other severe or unusual events’ category includes reports of adverse events that do not meet any other pre-defined events outlined in the [Infectious Diseases Protocol: Appendix 1](#) but are assessed to be clinically important or epidemiologically interesting.¹ These events usually require medical attention but do not necessarily meet either the [medically important event](#) definition or the serious AEFI definition. Serious AEFIs are described in the [Serious AEFI section](#). The number of AEFI reports and reporting rate for each adverse event are presented in [Appendix A](#).

Medically Important Events

Some selected adverse events are defined as “medically important,” based on the World Health Organization’s (WHO) guidance, regardless of whether they meet the serious AEFI definition. These types of events may jeopardize the patient or may require intervention to prevent an outcome described in the serious definition. The full list of medically important events are listed in the [technical notes](#).

There were 694 reports with medically important events, representing 3.0% of all reports. The most frequently reported medically important event was events managed as anaphylaxis (n=515), of which 39 met the definition of a serious AEFI (7.6%). Of all 515 reports of events managed as anaphylaxis: 494 received epinephrine, 462 were seen in the emergency department and 383 were fully recovered at the time of reporting. See this [resource](#) for more information on management of anaphylaxis following immunization in the community.⁷

Adverse events of special interest (AESIs) for COVID-19 vaccines

Several [adverse events of special interest \(AESIs\) for COVID-19 vaccines](#) have been identified by international health authorities based on a theoretical rationale for a possible association with COVID-19 vaccines. Reporting of AESIs for COVID-19 vaccines enables enhanced monitoring of events which may otherwise not be captured in a passive surveillance system.

There were 1,753 reports with COVID-19 vaccine-specific AESIs, representing 7.6% of all reports. Of the 1,753 reports, 763 met the definition of a serious AEFI. The number of AEFI reports and reporting rate for each AESI by vaccine product are presented in [Appendix A](#).

MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN AND ADULTS

In Ontario, 15 reports of multisystem inflammatory syndrome in children and adults (MIS-C/A) have been reported to date, with 14 of these reports meeting the provincial case definition. The 14 cases include 9 following Pfizer-BioNTech Comirnaty COVID-19 and 5 following Moderna Spikevax COVID-19 vaccine. All reports of MIS-C/A are assessed using the Brighton Collaboration standard definition of MIS-C/A.⁸ Six reports among persons under 21 years of age met level 1 of the Brighton Collaboration case definition of MIS-C and three reports met level 2A. Among persons 21 years of age and older, based on the clinical presentation and other indicators, three reports met level 1 of the Brighton Collaboration case definition of MIS-A and two reports had insufficient evidence to meet level 1, 2, or 3 (i.e., met level 4 diagnostic certainty) of the case definition.

MYOCARDITIS/PERICARDITIS

Rare myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining around the heart) events have been reported following vaccination with COVID-19 mRNA vaccines.⁹ Information from vaccine safety monitoring systems and evidence from multiple observational studies across many countries support an association between COVID-19 mRNA vaccines and an increased risk of myocarditis/pericarditis.¹⁰⁻¹² Information to date indicates that these events occur more commonly after the second dose, within the week following vaccination (typically within 4-5 days), mainly in adolescents/young adults 12 to 29 years of age, and more often in males than females.⁹

Vaccine safety surveillance data in Canada suggest relatively higher rates of myocarditis/pericarditis reported after Moderna Spikevax COVID-19 vaccine compared to Pfizer-BioNTech Comirnaty COVID-19 vaccine.¹³ Similar trends have been observed in Ontario’s vaccine safety surveillance data where the reporting rates of myocarditis/pericarditis was observed to be higher following vaccination with Moderna Spikevax COVID-19 vaccine compared to Pfizer-BioNTech Comirnaty COVID-19 vaccine in the 18 to 24 year old age group, particularly among males.¹² Ontario issued a [preferential recommendation](#) of the use of Pfizer-BioNTech Comirnaty COVID-19 vaccine as a primary series for individuals aged 18 to

24 year olds on September 29, 2021 and later expanded this to individuals aged 12 to 29 years of age to align with the updated NACI recommendation.^{14,15} Ontario COVID-19 [vaccine guidance](#) provides more detailed information on eligibility for booster doses by age and product. Ontario is continuing to monitor these events in collaboration with its partners and updates can be found within this report and on the PHAC [website](#).⁵ For more information on this topic, see [PHO's Focus On: Myocarditis and Pericarditis after COVID-19 mRNA Vaccines](#) and additional in-depth analysis in [Myocarditis and Pericarditis Following Vaccination with COVID-19 mRNA Vaccines in Ontario: December 13, 2020 to November 21, 2021](#).^{16,17}

As of December 3, 2023, there have been 821 reports of myocarditis or pericarditis following receipt of COVID-19 mRNA vaccines in Ontario. These reports have been identified through case-level review of all reported AEFIs. Of these, 213 (25.9%) were diagnosed with myocarditis and 404 (49.2%) were diagnosed with pericarditis. The remaining 204 (24.8%) were diagnosed with perimyocarditis (n=37), myopericarditis (n=156) and myocarditis/pericarditis (n=11).

The 213 reports of myocarditis have been assessed using the [Brighton Collaboration case definition for myocarditis](#); 191 reports met Brighton levels of diagnostic certainty 1, 2 or 3 (89.7%), 22 reports had insufficient evidence to meet level 1, 2, or 3 of the case definition (10.3%).¹⁸ Of the 404 reports of pericarditis assessed using the [Brighton Collaboration case definition for pericarditis](#), 206 reports met Brighton levels of diagnostic certainty 1, 2, or 3 (51.0%) and 198 reports had insufficient evidence to meet level 1, 2 or 3 of the case definition (49.0%).¹⁸ The remaining 204 reports diagnosed with perimyocarditis, myopericarditis or myocarditis/pericarditis were assessed against both Brighton Collaboration case definition for myocarditis and pericarditis to see if they meet either one of two definitions; of these, 192 (94.1%) met Brighton levels of diagnostic certainty 1, 2, or 3 for either myocarditis or pericarditis, and 12 reports had insufficient evidence to meet level 1, 2, or 3 (5.9%).

Based on 821 reports of myocarditis or pericarditis, the overall crude reporting rate is 21.2 per million doses of mRNA vaccines administered. The highest reporting rates were observed in younger age groups (12-17 and 18-24 years) and among males. The highest reporting rate was observed for males aged 18-24 years of age following dose 2, at 201.6 events per million doses administered. [Table A3](#) in Appendix A presents the reporting rate of myocarditis or pericarditis by age group, gender and dose number. The reporting rates are calculated by including all reports of myocarditis or pericarditis identified through case-level review, regardless of whether they meet the Brighton Collaboration case definition for myocarditis or pericarditis.

THROMBOSIS WITH THROMBOCYTOPENIA SYNDROME (TTS)

Thrombosis with thrombocytopenia syndrome (TTS) is a serious health condition characterized by the presence of acute venous or arterial thrombosis (blood clot) with new onset thrombocytopenia (low levels of platelets), and no known recent exposure to heparin. TTS emerged in 2021 as a new adverse event following immunization with COVID-19 adenoviral vector-based vaccines, including AstraZeneca Vaxzevria/COVISHIELD and Janssen Jcovden COVID-19 vaccines.¹⁹ Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) refers to the clinical syndrome of TTS, in addition to laboratory tests that confirm platelet activation (i.e., anti-platelet 4 antibodies). The province [announced](#) a pause on the administration of first doses of the AstraZeneca Vaxzevria COVID-19 vaccine on May 11, 2021, due to an observed increase in reports of TTS/VITT in Ontario. More information on TTS and VITT can be found on [PHO's Synthesis on COVID-19 Viral Vector Vaccines and Rare Blood Clots](#) and Ontario's COVID-19 Science Advisory Table scientific briefs on [Vaccine-Induced Immune Thrombotic Thrombocytopenia \(VITT\) Following Adenovirus Vector COVID-19 Vaccination](#).^{20,21}

There have been 21 reports of TTS following the AstraZeneca Vaxzevria COVID-19 vaccine COVID-19 vaccine in Ontario (including one probable TTS), with the most recent event having a vaccination date of May 6, 2021. All events were following the first dose of AstraZeneca Vaxzevria/COVISHIELD COVID-19 vaccine. Based on the number of first doses of AstraZeneca Vaxzevria/COVISHIELD COVID-19 vaccines administered in Ontario to date, the reporting rate of TTS based on 21 reports is 2.4 per 100,000 first doses administered (approximately 1 in 41,000). The reporting rate of VITT (as a subtype of TTS) based on 16 reports is 1.9 per 100,000 first doses administered (approximately 1 in 54,000). Of the 21 reports, 16 are confirmed as VITT with positive anti-PF4 antibody test results. The remaining five TTS events that are not classified as VITT have had VITT ruled out through testing (n=4) or did not have confirmatory tests ordered (n=1). There has been one report of death recorded in CCM in an individual with VITT. A Coroner's investigation determined that the immediate causes of death included Vaccine-induced Immune Thrombotic Thrombocytopenia (VITT). See [Appendix A](#) for the number of TTS/VITT reports by vaccine product.

As part of vaccine safety surveillance at the national level, the [Advisory Committee on Causality Assessment \(ACCA\)](#) has conducted a review of reports of TTS following COVID-19 vaccines.²² ACCA is a committee of experts who review reports of AEFIs to determine whether an event was likely to have been causally related to a given vaccine.

ACCA reviewed 103 potential TTS reports following receipt of any COVID-19 vaccine from across Canada. Among these reports, 37 were found to be “consistent with causal association to immunization” using the [World Health Organization's \(WHO\) causality assessment classification](#), including 16 from Ontario.²³ All 16 events followed administration of a viral vector vaccine and all occurred between March and May 2021. A national summary of the [ACCA assessment results](#) is published online.²⁴

Serious AEFIs

In Ontario, AEFIs that meet the serious definition are events that required hospital admission and reports of death (see the [technical notes](#) for a full definition).

There were 1,264 AEFI reports classified as serious, representing 5.5% of all AEFI reports and a serious AEFI reporting rate of 3.2 per 100,000 doses administered for all vaccine products combined. Of the 1,264 reports meeting the serious definition, 1,222 reports had a hospital admission related to the adverse event and 42 were reports of deaths. See [Table 1](#) for serious AEFI reporting rate by vaccine product. As a comparison, the proportion of AEFIs defined as serious for all vaccines administered in Ontario ranged from 2.8% to 5.0% between 2012 and 2018.²⁵

AEFI REPORTS REQUIRING HOSPITALIZATION

Of the 1,222 reports of hospitalization, 479 were recovered at the time of reporting, 546 were not yet recovered when the investigation was completed but likely to recover, and 105 reported persistent or significant disability/incapacity related to the adverse event. Due to the relatively short follow-up time for AEFIs reported in CCM, it is uncertain whether these disability/incapacity will eventually resolve, but had not yet resolved at the time of reporting. The remaining reports had unknown outcome at the time of reporting.

AEFI REPORTS WITH FATAL OUTCOME

In Ontario, reports of death that meet the provincial AEFI surveillance case definition are those that are temporally associated with vaccination, where no other clear cause of death can be established. Similar to other events, reports of deaths are thoroughly investigated by the local PHU through the collection of relevant information including a cause of death (e.g., autopsy or Coroner's report). **It is important to note that these reports should not be interpreted as causally related with receipt of a vaccine.**

As of December 3, 2023, there are 42 reports of death temporally associated with receipt of COVID-19 vaccine that met the provincial surveillance case definition. There was one death where AEFI may have been a contributing factor of death; in this death, a Coroner's investigation determined that the immediate causes of death included VITT.

PHO continues to conduct continuous monitoring of the safety of COVID-19 vaccines in collaboration with its partners, including individual case review of all serious AEFIs and daily analysis of surveillance data for vaccine safety signals.

Geography

Table 4. Number of AEFI reports and reporting rates by public health unit and region: Ontario, December 13, 2020 to December 3, 2023

Public Health Unit Name	Number of AEFI reports received to date	Reporting rate per 100,000 doses administered
Northwestern Health Unit	195	88.5
Thunder Bay District Health Unit	141	31.9
TOTAL NORTH WEST	336	50.7
Algoma Public Health	161	48.8
North Bay Parry Sound District Health Unit	207	57.9
Porcupine Health Unit	147	69.4
Public Health Sudbury & Districts	454	81.3
Timiskaming Health Unit	108	122.3
TOTAL NORTH EAST	1,077	69.6
Eastern Ontario Health Unit	604	104.3
Hastings Prince Edward Public Health	227	47.9
Kingston, Frontenac and Lennox & Addington Public Health	486	74.9
Leeds, Grenville & Lanark District Health Unit	419	74.0
Ottawa Public Health	2,454	78.5
Renfrew County and District Health Unit	287	101.5
TOTAL EASTERN	4,477	78.8
Durham Region Health Department	3,268	173.1
Haliburton, Kawartha, Pine Ridge District Health Unit	567	103.7
Peel Public Health	1,490	40.6

Public Health Unit Name	Number of AEFI reports received to date	Reporting rate per 100,000 doses administered
Peterborough Public Health	299	70.5
Simcoe Muskoka District Health Unit	852	53.2
York Region Public Health	1,861	59.0
TOTAL CENTRAL EAST	8,337	73.9
Toronto Public Health	2,678	33.6
TOTAL TORONTO	2,678	33.6
Chatham-Kent Public Health	82	29.7
Grey Bruce Health Unit	199	42.6
Huron Perth Public Health	423	102.0
Lambton Public Health	606	175.8
Middlesex-London Health Unit	346	24.6
Southwestern Public Health	471	83.8
Windsor-Essex County Health Unit	395	36.8
TOTAL SOUTH WEST	2,522	55.5
Brant County Health Unit	168	43.4
City of Hamilton Public Health Services	646	42.8
Haldimand-Norfolk Health Unit	67	22.4
Halton Region Public Health	950	56.1
Niagara Region Public Health	556	42.9
Region of Waterloo Public Health and Emergency Services	798	50.5
Wellington-Dufferin-Guelph Public Health	515	60.0
TOTAL CENTRAL WEST	3,700	48.5
TOTAL ONTARIO	23,127	58.1

Note: Orientation of AEFI reports by geography is based the case's public health unit of residence at the time of the adverse event. This does not represent the location of vaccine administration. Reporting rates should not be interpreted as incidence rates. In the context of a passive AEFI surveillance system, a higher overall reporting rate of AEFIs does not necessarily suggest a vaccine safety concern; rather, it is an indicator of a robust passive vaccine safety surveillance system. Reporting rates are valuable estimates for comparing to other passive surveillance systems and for monitoring reporting trends over time.

Data Source: CCM, COVaxON (see [technical notes](#) for details on data sources)

Technical Notes

Data Sources

- The data for this report were based on:
- AEFI information from the Public Health Case and Contact Management Solution (CCM) extracted on **December 4, 2023 at approximately 8:30 a.m.**
- Doses administered data from the Ontario Ministry of Health's COVaxON application extracted on **December 4, 2023 at approximately 7:00 a.m.** Doses administered out of province and doses administered with non-Ontario stock were excluded from the doses administered data used for this report. Methodology used to calculate the number of doses administered are documented in PHO's [COVID-19 Vaccine Uptake in Ontario report](#).²⁶

Data Caveats

- Data presented in this report only represent AEFIs reported to public health units and recorded in CCM. As a result, all counts will be subject to varying degrees of reporting bias, including underreporting, particularly for mild or common reportable events, as well as stimulated (elevated) reporting, which can occur in response to media coverage and increased public awareness.
- CCM and COVaxON are dynamic reporting systems which allow ongoing updates to data previously entered. As a result, data extracted from CCM and COVaxON represent a snapshot at the time of data extraction and may differ from previous or subsequent reports.
- Data corrections or updates can result in AEFI reports being removed and/or updated from past reports and may result in counts differing from past publicly reported AEFIs.

Methods

- For provincial surveillance reporting, an adverse event must occur after receiving the vaccine and meet the MOH [AEFI case definition](#).¹ Data presented in this report only includes AEFI reports with a confirmed case classification and an association with a COVID-19 vaccine in CCM at the time of data extraction.
- AEFI reports from CCM where the Disposition was reported as ENTERED IN ERROR, DOES NOT MEET DEFINITION or DUPLICATE – DO NOT USE, or any variation on these values have been excluded. AEFI reports from CCM where the Status was reported as MERGED-OBSOLETE have also been excluded.
- AEFI reports with a missing date of vaccine administration have been excluded. If an AEFI report has more than one vaccination entered (i.e., it was unclear if the adverse event was attributed to the first or the second dose of the series), then the administration date of the first dose was used for the analysis.
- Each AEFI report refers to an individual who reported an adverse event after receiving a dose of COVID-19 vaccine. An AEFI report may contain multiple adverse events. Therefore, the total number of adverse events can exceed the number of individual AEFI reports reported in a given time frame. AEFI reports that did not have an adverse event reported at the time of data extraction have been excluded.

- AEFI reporting rates are calculated using the number of COVID-19 vaccine-specific AEFIs reported in a given time period in Ontario divided by doses of COVID-19 vaccines administered in the same time period in Ontario. AEFIs that are reported in Ontario following vaccines that were administered outside of Canada with a Health Canada-approved vaccine are included in the calculation of reporting rates. The number of such reports are small and has minimal impact on the reporting rates.
- On October 14, 2021, changes were made in CCM to enable reporting on Sex and Gender separately; previously, sex and gender were reported interchangeably under the Gender field. Male/Female information presented in this report are sourced from the Sex field in CCM and are intended to represent sex assigned at birth. The doses administered data from the COVaxON application are presented by gender, which is used as a proxy for doses administered by sex in calculating sex-specific reporting rates.
- Dose number is extracted from CCM. It represents the dose number of the immunization that is associated with the adverse event. Since dose number was not a system-mandatory field in CCM during the initial implementation of the system, there are records with missing dose number information. When a dose number was missing or reported as unknown in CCM, the individual's immunization records in COVaxON application were examined to identify the dose number of the immunization that was associated with the AEFI, if available.
- Serious AEFIs are defined using the [World Health Organization \(WHO\) standard definition](#):²⁷ an AEFI that results in death, is life-threatening, requires in-patient hospitalization or prolongs an existing hospitalization, results in persistent or significant disability/incapacity, or in a congenital anomaly/birth defect. Due to data limitations and the relatively brief follow-up period of AEFIs reported in Ontario, AEFI reports that meet the serious definition typically have an in-patient hospitalization or death reported. In-patient hospitalization is defined as having a hospital admission recorded in CCM. Deaths are defined as reporting 'fatal' in the outcome field in CCM.
- Some selected adverse events can be defined as "medically important," based on the World Health Organization's (WHO) guidance, regardless of whether they meet the serious AEFI definition. These types of events may jeopardize the patient or may require intervention to prevent an outcome described in the serious definition (e.g., hospitalization); "medically important" events may be defined after applying medical and scientific judgement. In Ontario, the specific events under surveillance that align with this definition include: acute disseminated encephalomyelitis (ADEM), events managed as anaphylaxis, encephalitis/encephalopathy, Guillain-Barré syndrome (GBS), intussusception, meningitis, myelitis/transverse myelitis and thrombocytopenia.
- All reports of events managed as anaphylaxis, GBS, myocarditis, and TTS/VITT are further assessed using the internationally recognized case definition from the Brighton Collaboration. An independent review of these cases is completed and a preliminary score is assigned based on this case definition. This score is not a measure of severity but rather reflects the level of diagnostic certainty, with level 1 being the most highly specific for the condition.

- Several adverse events of special interest (AESI) following administration of COVID-19 vaccine(s) were selected for surveillance.²⁸ These are: vaccine-associated enhanced disease, multisystem inflammatory syndrome in children and adults, acute respiratory distress syndrome, acute cardiovascular injury, myocarditis/pericarditis, coagulation disorder (including thrombotic events), thrombosis with thrombocytopenia syndrome (TTS) and vaccine-induced immune thrombotic thrombocytopenia (VITT), acute kidney injury, acute liver injury, anosmia and/or ageusia, chilblain-like lesions, single organ cutaneous vasculitis, erythema multiforme, acute pancreatitis, rhabdomyolysis, and subacute thyroiditis.
- Orientation of case counts by geography is based on the Permanent Health Unit in CCM. Permanent Health Unit refers to the case's public health unit of residence at the time of adverse event. Cases for which the Permanent Health Unit was reported as MOH-PHO (to signify a case that is not a resident of Ontario) have been excluded from the analyses.

References

1. Ontario. Ministry of Health. Infectious diseases protocol: appendix 1: provincial case definitions for diseases of public health significance: adverse events following immunization (AEFIs) [Internet]. Toronto, ON: King's Printer for Ontario; 2023 [cited 2023 Nov 28]. Available from: <https://files.ontario.ca/moh-ophs-adverse-events-following-immunization-en-2023.pdf>
2. Ontario Agency for Health Protection and Promotion (Public Health Ontario). COVID-19 vaccines [Internet]. Toronto, ON: King's Printer for Ontario; 2023 [modified 2021 Jun 17; cited 2023 Nov 23]. Available from: <https://www.publichealthontario.ca/en/diseases-and-conditions/infectious-diseases/respiratory-diseases/novel-coronavirus/vaccines>
3. Ontario Agency for Health Protection and Promotion (Public Health Ontario). Focus on: how vaccine safety is monitored in Canada [Internet]. Toronto, ON: Queen's Printer for Ontario; 2020 [cited 2021 Jan 16]. Available from: <https://www.publichealthontario.ca/-/media/documents/ncov/vaccines/2020/12/vaccine-safety-surveillance-canada.pdf?la=en>
4. Ontario Agency for Health Protection and Promotion (Public Health Ontario). Vaccine safety surveillance archive [Internet]. Toronto, ON: Queen's Printer for Ontario; 2020 [modified 2020 Dec 16; cited 2021 Jan 16]. Available from: <https://www.publichealthontario.ca/en/data-and-analysis/infectious-disease/vaccine-safety/vaccine-safety-surveillance-archive>
5. Government of Canada. COVID-19 vaccine safety in Canada [Internet]. Ottawa, ON: Government of Canada; 2023 [modified 2023 Sept 29; cited 2023 Nov 28]. Available from: <https://health-infobase.canada.ca/covid-19/vaccine-safety/>
6. Public Health Agency of Canada; National Advisory Committee on Immunization. An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI): recommendations on the use of COVID-19 vaccines [Internet]. Ottawa, ON: Government of Canada; 2021 [cited 2021 Nov 10]. Available from: <https://www.canada.ca/content/dam/phac-aspc/documents/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines/recommendations-use-covid-19-vaccines-en.pdf>
7. Ontario Agency for Health Protection and Promotion (Public Health Ontario). Management of anaphylaxis following immunization in the community [Internet]. 1 st revision. Toronto, ON: Queen's Printer for Ontario; 2022 [cited 2023 Nov 28]. Available from: <https://www.publichealthontario.ca/-/media/documents/ncov/vaccines/2021/03/managing-anaphalaxis-following-immunization.pdf?la=en>
8. Vogel TP, Top KA, Karatzios C, Hilmers DC, Tapia LI, Mocerri P, et al. Multisystem inflammatory syndrome in children and adults (MIS-C/A): Case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2021;39(22):3037-49. Available from: <https://doi.org/10.1016/j.vaccine.2021.01.054>
9. Public Health Agency of Canada; National Advisory Committee on Immunization; Committee to Advise on Tropical Medicine and Travel. Canadian immunization guide [Internet]. Evergreen ed. Ottawa, ON: Government of Canada; 2023 [modified 2023 Sep 13; cited 2023 Sep 13]. Part 4, Active vaccines: covid-19 vaccine – uncommon, rare and very rare adverse events. Available from: <https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-26-covid-19-vaccine.html#a10.2>

10. Hudsby A, Kober L. COVID-19 mRNA vaccination and myocarditis or pericarditis. *Lancet*. 2022;399(10342):2168-9. Available from: [https://doi.org/10.1016/S0140-6736\(22\)00842-X](https://doi.org/10.1016/S0140-6736(22)00842-X)
11. Oster ME, Shay DK, Su JR, Gee J, Creech CB, Broder KR, et al. Myocarditis cases reported after mRNA-based COVID-19 vaccination in the US from December 2020 to August 2021. *JAMA*. 2022;327(4):331–40. Available from: <https://doi.org/10.1001/jama.2021.24110>
12. Buchan SA, Seo CY, Johnson C, Alley S, Kwong JC, Nasreen S, et al. Epidemiology of myocarditis and pericarditis following mRNA vaccination by vaccine product, schedule, and interdose interval among adolescents and adults in Ontario, Canada. *JAMA Netw Open*. 2022;5(6):e2218505. Available from: <https://doi.org/10.1001/jamanetworkopen.2022.18505>
13. Public Health Agency of Canada. Statement from the Council of Chief Medical Officers of Health (CCMOH): update on COVID-19 vaccines and the risk of myocarditis and pericarditis [Internet]. Ottawa, ON: Government of Canada; 2021 [cited 2021 Oct 05]. Available from: <https://www.canada.ca/en/public-health/news/2021/10/statement-from-the-council-of-chief-medical-officers-of-health-ccmoh-update-on-covid-19-vaccines-and-the-risk-of-myocarditis-and-pericarditis.html>
14. Government of Ontario. Statement: Ontario recommends the use of Pfizer-BioNTech COVID-19 vaccine for individuals aged 18-24 years old [Internet]. Toronto, ON: Queen's Printer for Ontario; 2021 [cited 2021 Oct 05]. Available from: <https://news.ontario.ca/en/statement/1000907/ontario-recommends-the-use-of-pfizer-biontech-covid-19-vaccine-for-individuals-aged-18-24-years-old>
15. Ontario. Ministry of Health. COVID-19 Vaccine Information Sheet (age 12+) [Internet]. Toronto, ON: Queen's Printer for Ontario; 2021 [cited 2022 Jan 12]. Available from: https://www.health.gov.on.ca/en/pro/programs/publichealth/coronavirus/docs/vaccine/COVID-19_vaccine_info_sheet.pdf
16. Ontario Agency for Health Protection and Promotion (Public Health Ontario). Myocarditis and pericarditis after COVID-19 mRNA vaccines. 1st revision, March 2022. Toronto, ON: Queen's Printer for Ontario; 2022 [cited 2022 Mar 30]. Available from: https://www.publichealthontario.ca/-/media/documents/ncov/vaccines/2021/11/myocarditis-pericarditis-mrna-vaccines.pdf?sc_lang=en%20
17. Ontario Agency for Health Protection and Promotion (Public Health Ontario). Myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in Ontario: December 13, 2020 to November 21, 2021. Toronto, ON: Queen's Printer for Ontario; 2022 [cited 2022 Feb 8]. Available from: https://www.publichealthontario.ca/-/media/documents/ncov/epi/covid-19-myocarditis-pericarditis-vaccines-epi.pdf?sc_lang=en
18. Tejtel SKS, Munoz FM, et al. Myocarditis and pericarditis: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data. *Vaccine*. 2022 Mar;40(10):1499-1511. Available from: <https://doi.org/10.1016/j.vaccine.2021.11.074>.
19. Task Force for Global Health, Brighton Collaboration. Interim case definition of thrombosis with thrombocytopenia syndrome (TTS) [Internet]. Decatur, GA: Task Force for Global Health; 2021 [cited 2022 Mar 26]. Available from: <https://brightoncollaboration.us/thrombosis-with-thrombocytopenia-syndrome-interim-case-definition/>

20. Ontario Agency for Health Protection and Promotion (Public Health Ontario). COVID-19 viral vector vaccines and rare blood clots – vaccine safety surveillance in action. Toronto, ON: Queen’s Printer for Ontario; 2021 [cited 2021 Oct 13]. Available from: https://www.publichealthontario.ca/-/media/Documents/nCoV/Vaccines/2021/03/covid-19-focus-on-viral-vector-based-vaccines.pdf?rev=121b33caa76649019a7023762a18dfa2&sc_lang=en
21. Pai M, Chan B, Stall NM, Grill A, Ivers N, Maltsev A, et al. Vaccine-induced immune thrombotic thrombocytopenia (VITT) following adenovirus vector COVID-19 vaccination. Science Briefs of the Ontario COVID-19 Science Advisory Table. 2021;2(17). Available from: <https://doi.org/10.47326/ocsat.2021.02.17.2.0>
22. Public Health Agency of Canada; National Advisory Committee on Immunization. Advisory committee on causality assessment [Internet]. Ottawa, ON: Government of Canada; 2023 [cited 2023 Sep 25]. Available from: <https://www.canada.ca/en/public-health/services/immunization/vaccine-safety/advisory-committee-causality-assessment.html>
23. World Health Organization. Causality assessment of an adverse event following immunization (AEFI): user manual for the revised WHO classification second edition, 2019 update. Geneva, CH: World Health Organization; 2019. [cited 2023 Sep 25]. Available from: <https://iris.who.int/bitstream/handle/10665/340802/9789241516990-eng.pdf?sequence=1>
24. Public Health Agency of Canada; National Advisory Committee on Immunization. Thrombosis with thrombocytopenia syndrome: findings from the advisory committee on causality assessment [Internet]. Ottawa, ON: Government of Canada; 2023 [cited 2023 Sep 25]. Available from: <https://www.canada.ca/en/public-health/services/immunization/vaccine-safety/advisory-committee-causality-assessment/thrombosis-thrombocytopenia-syndrome-findings.html>
25. Ontario Agency for Health Protection and Promotion (Public Health Ontario). Annual report on vaccine safety in Ontario, 2018 [Internet]. Toronto, ON: Queen’s Printer for Ontario; 2019 [cited 2021 Jan 26]. Available from: <https://www.publichealthontario.ca/-/media/documents/a/2019/annual-vaccine-safety-report-2018.pdf?la=en>
26. Ontario Agency for Health Protection and Promotion (Public Health Ontario). COVID-19 vaccine uptake in Ontario: December 14, 2020 to September 10, 2023. Toronto, ON: King’s Printer for Ontario; 2023. Available from: <https://www.publichealthontario.ca/-/media/documents/ncov/epi/covid-19-vaccine-uptake-ontario-epi-summary.pdf?la=en>
27. ICH Expert Working Group. ICH harmonised tripartite guideline: clinical safety data management: definitions and standards for expedited reporting E2A [Internet]. Version 4. Geneva: ICH; 1994 [cited 2021 Jan 16]. Available from: http://database.ich.org/sites/default/files/E2A_Guideline.pdf
28. Ontario Agency for Health Protection and Promotion (Public Health Ontario). Adverse events of special interest (AESIs) for COVID-19 vaccines surveillance. Toronto, ON: Queen's Printer for Ontario; 2020 [cited 2021 Jul 19]. Available from: <https://www.publichealthontario.ca/-/media/documents/ncov/vaccines/2020/12/covid-19-guidance-aesis.pdf?la=en>

Appendix A

Table A1. Number of AEFI reports by adverse event and COVID-19 vaccine product: Ontario, December 13, 2020 to December 3, 2023

Adverse event	Pfizer-BioNTech Comirnaty	Pfizer-BioNTech Comirnaty Bivalent BA.4/5	Pfizer-BioNTech Comirnaty XBB.1.5	Moderna Spikevax	Moderna Spikevax Bivalent BA.1	Moderna Spikevax Bivalent BA.4/5	Moderna Spikevax XBB.1.5	AstraZeneca Vaxzevria/COVISHIELD	Janssen Jcovden (Johnson & Johnson)	Novavax Nuvaxovoid	All vaccine products combined
Other severe or unusual events*	4,187	56	5	1,758	33	6	8	460	11	14	6,538
Allergic skin reactions	3,375	36	3	1,474	21	7	2	279	4	10	5,212
Pain/redness/swelling at the injection site	1,574	28	9	2,109	13	15	11	324	3	3	4,089
Rash	1,364	19	3	875	12	1	5	189	3	2	2,475
Anaesthesia/paraesthesia	1,209	8	1	398	8	2	5	215	6	8	1,860
Adenopathy/lymphadenopathy	866	13	0	368	5	2	0	50	0	0	1,304
Arthritis/arthralgia	710	11	1	256	13	3	0	107	0	0	1,101
Fever in conjunction with another reportable event	473	6	1	389	5	0	0	171	1	3	1,050
Severe vomiting/diarrhea	559	5	2	305	6	3	0	149	1	3	1,033

Adverse event	Pfizer-BioNTech Comirnaty	Pfizer-BioNTech Comirnaty Bivalent BA.4/5	Pfizer-BioNTech Comirnaty XBB.1.5	Moderna Spikevax	Moderna Spikevax Bivalent BA.1	Moderna Spikevax Bivalent BA.4/5	Moderna Spikevax XBB.1.5	AstraZeneca Vaxzevria/ COVISHIELD	Janssen Jcovden (Johnson & Johnson)	Novavax Nuvaxovoid	All vaccine products combined
AESI - Myocarditis/pericarditis**	521	4	0	296	3	0	0	9	0	2	835
Event managed as anaphylaxis†	366	1	1	122	0	1	0	22	1	1	515
AESI – Coagulation disorder (including thrombotic events)	254	9	2	104	7	3	0	76	0	0	455
Bell's Palsy	226	8	1	96	3	0	0	15	0	0	349
Syncope (fainting) with injury	256	5	0	72	3	0	0	8	0	0	344
Cellulitis	47	0	1	212	0	1	0	23	0	0	284
AESI – Acute cardiovascular injury	144	2	0	74	4	1	2	19	0	0	246
Convulsions/ seizure	112	2	0	40	0	1	0	13	0	1	169
Thrombocytopenia†	55	0	0	16	2	1	0	20	1	0	95
Nodule	32	0	0	40	1	0	0	21	0	0	94
Paralysis	32	0	0	10	2	0	0	9	0	0	53
AESI – Anosmia, ageusia	31	0	0	13	0	0	0	4	0	0	48

Adverse event	Pfizer-BioNTech Comirnaty	Pfizer-BioNTech Comirnaty Bivalent BA.4/5	Pfizer-BioNTech Comirnaty XBB.1.5	Moderna Spikevax	Moderna Spikevax Bivalent BA.1	Moderna Spikevax Bivalent BA.4/5	Moderna Spikevax XBB.1.5	AstraZeneca Vaxzevria/ COVISHIELD	Janssen Jcovden (Johnson & Johnson)	Novavax Nuvaxovoid	All vaccine products combined
Guillain-Barré syndrome (GBS) [†]	16	0	0	11	0	0	0	17	0	0	44
AESI - Acute liver injury	24	0	1	12	0	0	0	2	0	0	39
AESI – TTS/VITT	4	0	0	3	0	0	0	21	0	0	28
AESI - Acute kidney injury	16	0	1	8	0	0	0	3	0	0	28
Oculorespiratory syndrome (ORS)	18	0	0	8	0	0	0	2	0	0	28
Myelitis/ transverse myelitis [†]	15	0	0	6	0	1	0	3	0	0	25
AESI – Single organ cutaneous vasculitis	12	0	0	6	0	0	0	4	0	0	22
AESI - Subacute thyroiditis	14	1	0	5	0	0	0	1	0	0	21
AESI – Chilblain-like lesions	15	0	0	5	0	0	0	1	0	0	21
AESI - Acute pancreatitis	12	0	0	5	0	0	0	1	0	0	18

Adverse event	Pfizer-BioNTech Comirnaty	Pfizer-BioNTech Comirnaty Bivalent BA.4/5	Pfizer-BioNTech Comirnaty XBB.1.5	Moderna Spikevax	Moderna Spikevax Bivalent BA.1	Moderna Spikevax Bivalent BA.4/5	Moderna Spikevax XBB.1.5	AstraZeneca Vaxzevria/ COVISHIELD	Janssen Jcovden (Johnson & Johnson)	Novavax Nuvaxovoid	All vaccine products combined
AESI - Rhabdomyolysis	7	0	0	7	1	0	0	1	0	0	16
AESI – Erythema multiforme	9	0	0	6	0	0	0	1	0	0	16
AESI - Multisystem inflammatory syndrome in children/adults	10	0	0	5	0	0	0	0	0	0	15
Encephalopathy/ encephalitis†	7	1	0	4	0	0	0	1	0	0	13
Infected abscess	2	0	0	6	0	0	0	0	0	0	8
Parotitis	6	1	0	1	0	0	0	0	0	0	8
AESI - Vaccine-associated enhanced disease	6	0	0	0	0	0	0	0	0	0	6
AESI – Acute respiratory distress syndrome	3	0	0	2	0	0	0	0	0	0	5
Kawasaki Disease	2	0	0	2	0	0	0	0	0	0	4
Sterile abscess	2	0	0	2	0	0	0	0	0	0	4

Adverse event	Pfizer-BioNTech Comirnaty	Pfizer-BioNTech Comirnaty Bivalent BA.4/5	Pfizer-BioNTech Comirnaty XBB.1.5	Moderna Spikevax	Moderna Spikevax Bivalent BA.1	Moderna Spikevax Bivalent BA.4/5	Moderna Spikevax XBB.1.5	AstraZeneca Vaxzevria/COVISHIELD	Janssen Jcovden (Johnson & Johnson)	Novavax Nuvaxovoid	All vaccine products combined
Meningitis	2	0	0	0	0	0	0	1	0	0	3
Acute disseminated encephalomyelitis (ADEM) [†]	1	0	0	0	0	0	0	0	0	0	1

Notes:

- The columns above for Pfizer-BioNTech Comirnaty and Moderna Spikevax COVID-19 vaccines include AEFIs associated with all indicated dosages: 3 mcg, 10 mcg and 30 mcg for Pfizer-BioNTech Comirnaty and 25 mcg, 50 mcg and 100 mcg for Moderna Spikevax. Moderna Spikevax BA.1 Bivalent (50 mcg), Moderna Spikevax BA.4/5 Bivalent (50 mcg) and Pfizer-BioNTech Comirnaty Bivalent BA.4/5 (10 mcg and 30 mcg) COVID-19 vaccines are presented separately and were previously recommended vaccine products before the approval of the XBB.1.5-containing COVID-19 mRNA vaccines. Currently, Pfizer-BioNTech Comirnaty XBB.1.5 and Moderna Spikevax XBB.1.5 COVID-19 vaccines are approved and recommended for vaccinating individuals who are not previously vaccinated and as additional doses for those previously vaccinated in approved age groups
- An AEFI report may contain multiple adverse events. Thus the sum of all adverse event-specific counts may not equal to the total number of AEFI reports. Some AEFI reports did not specify vaccine product received; these are included in the counts for all vaccine products combined.

* This category includes reports of death that are temporally associated with immunization and where no other clear cause of death was established; these reports should not be interpreted as causally related with vaccine. These reports are described in the [Serious AEFI section](#).

** The number of reports with 'AESI – Myocarditis/pericarditis' presented in this table is based on CCM data entry and may be different from the number of myocarditis or pericarditis reports that are presented in the [Myocarditis/Pericarditis section](#), which is based on case-level review. With the latter process, additional reports may be identified in those that are not yet classified as 'AESI – Myocarditis/pericarditis' or reports may be excluded if the case information does not support the report being classified as 'AESI – Myocarditis/pericarditis'. Refer to the [Myocarditis/Pericarditis section](#) for information on the number of myocarditis or pericarditis reports based on the latter process.

[†]Represents a medically important event.

Data Source: CCM

Table A2. Reporting rate per 100,000 doses administered by adverse event and COVID-19 vaccine product: Ontario, December 18, 2020 to December 3 , 2023

Adverse event	Pfizer-BioNTech Comirnaty	Pfizer-BioNTech Comirnaty Bivalent BA.4/5	Pfizer-BioNTech Comirnaty XBB.1.5	Moderna Spikevax	Moderna Spikevax Bivalent BA.1	Moderna Spikevax Bivalent BA.4/5	Moderna Spikevax XBB.1.5	AstraZeneca Vaxzevria/ COVISHIELD	Janssen Jcovden (Johnson & Johnson)	Novavax Nuvaxovoid	All vaccine products combined
Other severe or unusual events*	17.7	2.4	0.4	18.2	2.6	4.3	1.5	42.3	275.1	84.8	16.4
Allergic skin reactions	14.3	1.6	0.3	15.3	1.7	5.0	0.4	25.7	100.1	60.6	13.1
Pain/redness/ swelling at the injection site	6.7	1.2	0.8	21.9	1.0	10.7	2.0	29.8	75.0	18.2	10.3
Rash	5.8	0.8	0.3	9.1	1.0	0.7	0.9	17.4	75.0	12.1	6.2
Anaesthesia/ paraesthesia	5.1	0.3	0.1	4.1	0.6	1.4	0.9	19.8	150.1	48.4	4.7
Adenopathy/ lymphadenopathy	3.7	0.6	0.0	3.8	0.4	1.4	0.0	4.6	0.0	0.0	3.3
Arthritis/ arthralgia	3.0	0.5	0.1	2.7	1.0	2.1	0.0	9.8	0.0	0.0	2.8
Fever in conjunction with another reportable event	2.0	0.3	0.1	4.0	0.4	0.0	0.0	15.7	25.0	18.2	2.6
Severe vomiting/ diarrhea	2.4	0.2	0.2	3.2	0.5	2.1	0.0	13.7	25.0	18.2	2.6
AESI - Myocarditis/ pericarditis**	2.2	0.2	0.0	3.1	0.2	0.0	0.0	0.8	0.0	12.1	2.1

Adverse event	Pfizer-BioNTech Comirnaty	Pfizer-BioNTech Comirnaty Bivalent BA.4/5	Pfizer-BioNTech Comirnaty XBB.1.5	Moderna Spikevax	Moderna Spikevax Bivalent BA.1	Moderna Spikevax Bivalent BA.4/5	Moderna Spikevax XBB.1.5	AstraZeneca Vaxzevria/ COVISHIELD	Janssen Jcovden (Johnson & Johnson)	Novavax Nuvaxovoid	All vaccine products combined
Event managed as anaphylaxis†	1.5	0.0	0.1	1.3	0.0	0.7	0.0	2.0	25.0	6.1	1.3
AESI – Coagulation disorder (including thrombotic events)	1.1	0.4	0.2	1.1	0.6	2.1	0.0	7.0	0.0	0.0	1.1
Bell's Palsy	1.0	0.3	0.1	1.0	0.2	0.0	0.0	1.4	0.0	0.0	0.9
Syncope (fainting) with injury	1.1	0.2	0.0	0.7	0.2	0.0	0.0	0.7	0.0	0.0	0.9
Cellulitis	0.2	0.0	0.1	2.2	0.0	0.7	0.0	2.1	0.0	0.0	0.7
AESI – Acute cardiovascular injury	0.6	0.1	0.0	0.8	0.3	0.7	0.4	1.7	0.0	0.0	0.6
Convulsions/ seizure	0.5	0.1	0.0	0.4	0.0	0.7	0.0	1.2	0.0	6.1	0.4
Nodule	0.1	0.0	0.0	0.4	0.1	0.0	0.0	1.9	0.0	0.0	0.2
Thrombocytopenia†	0.2	0.0	0.0	0.2	0.2	0.7	0.0	1.8	25.0	0.0	0.2
AESI - Acute liver injury	0.1	0.0	0.1	0.1	0.0	0.0	0.0	0.2	0.0	0.0	0.1
AESI - Subacute thyroiditis	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.1
AESI - TTS/VITT	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.9	0.0	0.0	0.1

Adverse event	Pfizer-BioNTech Comirnaty	Pfizer-BioNTech Comirnaty Bivalent BA.4/5	Pfizer-BioNTech Comirnaty XBB.1.5	Moderna Spikevax	Moderna Spikevax Bivalent BA.1	Moderna Spikevax Bivalent BA.4/5	Moderna Spikevax XBB.1.5	AstraZeneca Vaxzevria/ COVISHIELD	Janssen Jcovden (Johnson & Johnson)	Novavax Nuvaxovoid	All vaccine products combined
AESI – Acute kidney injury	0.1	0.0	0.1	0.1	0.0	0.0	0.0	0.3	0.0	0.0	0.1
AESI – Anosmia, ageusia	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.4	0.0	0.0	0.1
AESI – Chilblain-like lesions	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.1
AESI – Single organ cutaneous vasculitis	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.4	0.0	0.0	0.1
Guillain-Barré syndrome (GBS)†	0.1	0.0	0.0	0.1	0.0	0.0	0.0	1.6	0.0	0.0	0.1
Myelitis/transverse myelitis†	0.1	0.0	0.0	0.1	0.0	0.7	0.0	0.3	0.0	0.0	0.1
Oculorespiratory syndrome (ORS)	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.2	0.0	0.0	0.1
Paralysis	0.1	0.0	0.0	0.1	0.2	0.0	0.0	0.8	0.0	0.0	0.1
AESI - Acute pancreatitis	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0
AESI - Multisystem inflammatory syndrome in children/adults	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0
AESI - Rhabdomyolysis	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.1	0.0	0.0	0.0

Adverse event	Pfizer-BioNTech Comirnaty	Pfizer-BioNTech Comirnaty Bivalent BA.4/5	Pfizer-BioNTech Comirnaty XBB.1.5	Moderna Spikevax	Moderna Spikevax Bivalent BA.1	Moderna Spikevax Bivalent BA.4/5	Moderna Spikevax XBB.1.5	AstraZeneca Vaxzevria/ COVISHIELD	Janssen Jcovden (Johnson & Johnson)	Novavax Nuvaxovoid	All vaccine products combined
AESI - Vaccine-associated enhanced disease	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
AESI – Acute respiratory distress syndrome	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
AESI – Erythema multiforme	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0
Acute disseminated encephalomyelitis (ADEM) [†]	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Encephalopathy/ encephalitis [†]	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0
Infected abscess	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Kawasaki Disease	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Meningitis	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0
Parotitis	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Sterile abscess	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

Notes:

- The columns above for Pfizer-BioNTech Comirnaty and Moderna Spikevax COVID-19 vaccines include AEFIs associated with all indicated dosages: 3 mcg, 10 mcg and 30 mcg for Pfizer-BioNTech Comirnaty and 25 mcg, 50 mcg and 100 mcg for Moderna Spikevax. Moderna Spikevax BA.1 Bivalent (50 mcg), Moderna Spikevax BA.4/5 Bivalent (50 mcg) and Pfizer-BioNTech Comirnaty Bivalent BA.4/5 (10 mcg and 30 mcg) COVID-19 vaccines are presented separately and were previously recommended vaccine products before the approval of the XBB.1.5-containing COVID-19 mRNA vaccines. Currently, Pfizer-BioNTech Comirnaty XBB.1.5 and Moderna Spikevax XBB.1.5 COVID-19 vaccines are approved and recommended for vaccinating individuals who are not previously vaccinated and as additional doses for those previously vaccinated in approved age groups.

- An AEFI report may contain multiple adverse events. Thus the sum of all adverse event-specific counts may not equal to the total number of AEFI reports. Some AEFI reports did not specify vaccine product received; these are included in the counts for all vaccine products combined.
 - Reporting rates for the Janssen Jcovden (Johnson & Johnson), Novavax Nuvaxovid and Moderna Spikevax Bivalent BA.4/5 COVID-19 vaccines should be interpreted with caution due to unstable reporting rates arising from small number of doses administered.
 - * This category includes reports of death that are temporally associated with immunization and where no other clear cause of death was established; these reports should not be interpreted as causally related with vaccine. These reports are described in the [Serious AEFI section](#).
 - ** The number of reports with 'AESI – Myocarditis/pericarditis' presented in this table is based on CCM data entry and may be different from the number of myocarditis or pericarditis reports that are presented in the [Myocarditis/Pericarditis section](#), which is based on case-level review. With the latter process, additional reports may be identified in those that are not yet classified as 'AESI – Myocarditis/pericarditis' or reports may be excluded if the case information does not support the report being classified as 'AESI – Myocarditis/pericarditis'. Refer to the [Myocarditis/Pericarditis section](#) for information on the number of myocarditis or pericarditis reports based on the latter process.
- †Represents a medically important event.
- Data Source:** CCM, COVaxON (see [technical notes](#) for details on data sources)

Table A3. Myocarditis/pericarditis crude reporting rates per million doses administered following COVID-19 mRNA vaccines: Ontario, December 13, 2020 to December 3, 2023

Age group (years)	All sex: All doses	All sex: Dose 1	All sex: Dose 2	All sex: Dose 3	All sex: Dose 4+	Females: All doses	Females: Dose 1	Females: Dose 2	Females: Dose 3	Females: Dose 4+	Males: All doses	Males: Dose 1	Males: Dose 2	Males: Dose 3	Males: Dose 4+
5-11	5.4	3.0	9.8	0.0	0.0	6.3	3.1	12.0	0.0	0.0	4.5	2.9	7.7	0.0	0.0
12-17	70.2	56.1	99.0	39.8	12.3	30.0	36.6	35.2	0.0	0.0	109.9	75.0	161.0	82.2	24.9
18-24	67.0	43.5	125.2	20.1	0.0	29.4	30.9	46.6	6.1	0.0	106.1	55.7	201.6	37.8	0.0
25-29	36.3	36.9	55.6	10.5	0.0	17.4	12.9	31.2	7.8	0.0	56.1	60.2	79.6	13.9	0.0
30-39	25.8	26.8	41.7	7.9	2.1	21.2	24.3	32.7	7.4	0.0	30.9	29.5	51.1	8.5	4.7
40-49	14.9	19.4	20.6	5.8	3.7	9.8	13.1	10.8	7.1	3.4	20.7	26.5	31.2	4.2	4.1
50-59	14.1	20.6	19.8	8.3	0.0	14.8	25.9	22.0	2.9	0.0	13.3	14.9	17.5	14.3	0.0
60-69	7.5	10.0	15.2	5.7	1.0	5.5	5.4	11.4	5.4	1.0	9.9	15.2	19.3	6.0	1.1
70-79	6.3	9.5	13.2	8.0	0.0	4.5	8.9	8.8	3.8	0.0	8.4	10.2	18.1	12.7	0.0
80+	4.3	3.2	12.9	3.4	0.8	1.7	0.0	5.5	2.9	0.0	8.1	8.0	24.0	4.2	2.0
Total	21.2	23.4	39.8	9.0	0.9	12.7	17.2	21.8	5.0	0.5	30.7	30.1	59.0	13.6	1.5

Note: Dose 4+ includes the 4th dose and all subsequent doses an individual has received.

All reports of myocarditis or pericarditis identified through case-level review (n=821) are included, regardless of the reports meeting the Brighton Collaboration case definition for myocarditis or pericarditis. There are no myocarditis/pericarditis AEFIs reported in age group 0-4 years.

Data Source: CCM, COVaxON (see [technical notes](#) for details on data sources)

Citation

Ontario Agency for Health Protection and Promotion (Public Health Ontario). Adverse events following immunization (AEFIs) for COVID-19 in Ontario: December 13, 2020 to December 3, 2023. Toronto, ON: King's Printer for Ontario; 2023.

Disclaimer

This document was developed by Public Health Ontario (PHO). PHO provides scientific and technical advice to Ontario's government, public health organizations and health care providers. PHO's work is guided by the current best available evidence at the time of publication.

The application and use of this document is the responsibility of the user. PHO assumes no liability resulting from any such application or use.

This document may be reproduced without permission for non-commercial purposes only and provided that appropriate credit is given to PHO. No changes and/or modifications may be made to this document without express written permission from PHO.

For Further Information

For more information, email ivpd@oahpp.ca.

Public Health Ontario

Public Health Ontario is an agency of the Government of Ontario dedicated to protecting and promoting the health of all Ontarians and reducing inequities in health. Public Health Ontario links public health practitioners, front-line health workers and researchers to the best scientific intelligence and knowledge from around the world.

For more information about PHO, visit publichealthontario.ca.